AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1929765 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference interpretations provided by therapists
Number of subjects: 64
Study 1929765 — intervention group
Group type: EXPERIMENTAL
Intervention: High proportions of transference interpretations
Number of subjects: 64
Study 1929765 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance
Number of subjects: 64
Study 7037162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 600 mg/m2 IV plus DTIC 600 mg/m2 IV day 1 (CD)
Number of subjects: 195
Study 7037162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 400 mg/m2 IV, DTIC 400 mg/m2 IV, and piperazinedione 4 mg/m2 IV on day 1 (PCD)
Number of subjects: 195
Study 7037162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment programs (CD and PCD)
Number of subjects: 195
Study 31665314 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months in year 1
Number of subjects: 126
Study 31665314 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once-weekly in year 2
Number of subjects: 126
Study 31665314 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab followed by Alendronate
Number of subjects: 126
Study 29703649 — intervention group
Group type: EXPERIMENTAL
Intervention: Index cholecystectomy (IC) performed within 48 hours
Number of subjects: 66
Study 29703649 — intervention group
Group type: COMPARATOR
Intervention: Delayed cholecystectomy (DC)
Number of subjects: 66
Study 29703649 — intervention group
Group type: EXPERIMENTAL
Intervention: Index cholecystectomy (IC)
Number of subjects: 66
Study 28215430 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-Only Intervention
Number of subjects: 790
Study 28215430 — intervention group
Group type: EXPERIMENTAL
Intervention: Child + Caregiver Intervention
Number of subjects: 790
Study 25754525 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endoscopic intervention with preventive pancreatic stenting
Number of subjects: 230
Study 25754525 — intervention group
Group type: COMPARATOR
Intervention: Early endoscopic intervention without pancreatic stenting
Number of subjects: 230
Study 25754525 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 230
Study 23812892 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive-behavioral therapy for adherence and depression with an alarmed pillbox
Number of subjects: 40
Study 23812892 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 20875810 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40mg/day)
Number of subjects: 102
Study 18505580 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected velocity walking in individuals with CFS
Number of subjects: 24
Study 18505580 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatively slow velocity walking (0.45 ms‐1) in individuals with CFS
Number of subjects: 24
Study 18505580 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatively fast velocity walking (1.30 +/‐ 0.24 ms‐1) in individuals with CFS
Number of subjects: 24
Study 18505580 — intervention group
Group type: COMPARATOR
Intervention: Self-selected velocity walking in matched controls
Number of subjects: 24
Study 16151062 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal approach
Number of subjects: 70
Study 16151062 — intervention group
Group type: COMPARATOR
Intervention: Subcostal approach
Number of subjects: 70
Study 12975222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (ChEIs)
Number of subjects: 5159
Study 10443750 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.035 IU/kg i.v.)
Number of subjects: 20
Study 10443750 — intervention group
Group type: COMPARATOR
Intervention: i.v. saline (control)
Number of subjects: 20
Study 8688258 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg kg‐1 and glycopyrronium 0.01 mg kg‐1
Number of subjects: 41
Study 8688258 — intervention group
Group type: COMPARATOR
Intervention: No antagonism of mivacurium
Number of subjects: 41
Study 8688258 — intervention group
Group type: COMPARATOR
Intervention: No neuromuscular blockers
Number of subjects: 41
Study 1990899 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms.kg‐1 infused over 3 h)
Number of subjects: 28
Study 1990899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6352035 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-cefoxitin (G-C)
Number of subjects: 37
Study 6352035 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin-cefoxitin (N-C)
Number of subjects: 37
Study 31727409 — intervention group
Group type: EXPERIMENTAL
Intervention: Resmetirom 80 mg
Number of subjects: 84
Study 31727409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 26517965 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR-walk
Number of subjects: 7
Study 26517965 — intervention group
Group type: COMPARATOR
Intervention: CON-walk
Number of subjects: 7
Study 25559905 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Plyometric Training (PPT)
Number of subjects: 24
Study 25559905 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Progressive Plyometric Training (NPPT)
Number of subjects: 24
Study 25559905 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 24
Study 24373006 — intervention group
Group type: EXPERIMENTAL
Intervention: 595-nm PDL with nonpurpuric settings (10 ms)
Number of subjects: 26
Study 24373006 — intervention group
Group type: EXPERIMENTAL
Intervention: 595-nm PDL with purpuric settings (1.5 ms)
Number of subjects: 26
Study 24373006 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 26
Study 21647559 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) - 10 min of ischemia and 10 min of reperfusion before parenchymal transection (10/10)
Number of subjects: 32
Study 21647559 — intervention group
Group type: COMPARATOR
Intervention: Control - Intermittent inflow occlusion (15 min of ischemia and 5 min of reperfusion repetitively; 15/5)
Number of subjects: 32
Study 19954550 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventative care program delivered at home over the first 12 months of life
Number of subjects: 0
Study 19954550 — intervention group
Group type: COMPARATOR
Intervention: Standard medical follow‐up
Number of subjects: 0
Study 19954550 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventative care program
Number of subjects: 0
Study 18085139 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Sifeng (EX‐UE 10), once each week, 3 consecutive sessions for one course
Number of subjects: 42
Study 18085139 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Sifeng (EX‐UE 10), once every two weeks, 3 consecutive sessions for one course
Number of subjects: 42
Study 18085139 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Lactein tablets, 1-2 tablets, 3 times daily for 4 weeks
Number of subjects: 42
Study 15467633 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sized antrostomy (less than 6 mm)
Number of subjects: 133
Study 15467633 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-sized antrostomy (more than 16 mm)
Number of subjects: 133
Study 15467633 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent accessory maxillary ostia, scarring within the ethmoid
Number of subjects: 133
Study 11758180 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (n = 50): instructed to lay on the same lateral posture with the fetal spine
Number of subjects: 100
Study 11758180 — intervention group
Group type: COMPARATOR
Intervention: Group B (n = 50): lay on the opposite side to the fetal spine
Number of subjects: 100
Study 11758180 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (n = 50)
Number of subjects: 100
Study 11758180 — intervention group
Group type: COMPARATOR
Intervention: Group B (n = 50)
Number of subjects: 100
Study 9165134 — intervention group
Group type: COMPARATOR
Intervention: Standard fraction RT (70 Gy)
Number of subjects: 159
Study 9165134 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus 6 mg/m2 of cisplatin (CDPP)
Number of subjects: 159
Study 9165134 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus 25 mg/m2 of carboplatin (CBDCA)
Number of subjects: 159
Study 9165134 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus either cisplatin or carboplatin
Number of subjects: 159
Study 9165134 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 159
Study 9165134 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus cisplatin or carboplatin
Number of subjects: 159
Study 9165134 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 159
Study 7962385 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted procreation methods (IUI, GIFT, IVF)
Number of subjects: 346
Study 7962385 — intervention group
Group type: COMPARATOR
Intervention: Ovulation induction alone and IPI
Number of subjects: 346
Study 7962385 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous natural conception
Number of subjects: 346
Study 2888159 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 48
Study 2888159 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 48
Study 2888159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 31300241 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Number of subjects: 60
Study 31300241 — intervention group
Group type: COMPARATOR
Intervention: MEOPA
Number of subjects: 60
Study 29357188 — intervention group
Group type: EXPERIMENTAL
Intervention: Screener for Substance and Behavioural Addictions (SSBA)
Number of subjects: 6000
Study 29357188 — intervention group
Group type: COMPARATOR
Intervention: Individual-behaviour screening instruments
Number of subjects: 6000
Study 27499458 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 7009
Study 27499458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7009
Study 24335056 — intervention group
Group type: EXPERIMENTAL
Intervention: A allele of CRY2 rs11605924
Number of subjects: 1443
Study 24335056 — intervention group
Group type: EXPERIMENTAL
Intervention: G allele of MTNR1B rs10830963
Number of subjects: 1443
Study 24335056 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-diet fat interactions for CRY2
Number of subjects: 1443
Study 24335056 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-diet fat interactions for MTNR1B
Number of subjects: 1443
Study 24334573 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (10 mg per day)
Number of subjects: 36
Study 24334573 — intervention group
Group type: COMPARATOR
Intervention: simvastatin/ezetimibe (10/10 mg per day)
Number of subjects: 36
Study 20826578 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct RIA assay
Number of subjects: 596
Study 20826578 — intervention group
Group type: EXPERIMENTAL
Intervention: LC/MS at Mayo
Number of subjects: 596
Study 20826578 — intervention group
Group type: EXPERIMENTAL
Intervention: LC/MS at Quest
Number of subjects: 596
Study 20826578 — intervention group
Group type: COMPARATOR
Intervention: RIA
Number of subjects: 596
Study 18812767 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized corneas
Number of subjects: 20
Study 18812767 — intervention group
Group type: COMPARATOR
Intervention: Optisol corneas
Number of subjects: 20
Study 16671429 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (S group)
Number of subjects: 16
Study 16671429 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (C group)
Number of subjects: 16
Study 12816783 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-iodine supplementation
Number of subjects: 324
Study 12816783 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-iodine supplementation
Number of subjects: 324
Study 12816783 — intervention group
Group type: COMPARATOR
Intervention: Control group (unsupplemented)
Number of subjects: 324
Study 12816783 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine supplementation
Number of subjects: 324
Study 10613996 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0
Study 10613996 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 0
Study 10613996 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 0
Study 9263147 — intervention group
Group type: EXPERIMENTAL
Intervention: Low load resistance exercise training program
Number of subjects: 49
Study 9263147 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 8230497 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (30 to 60 mEq daily for 3 years)
Number of subjects: 57
Study 8230497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 8230497 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate
Number of subjects: 57
Study 3764522 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose parenteral therapy
Number of subjects: 212
Study 3764522 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-dose parenteral therapy
Number of subjects: 212
Study 3764522 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral and lavage therapy
Number of subjects: 212
Study 3764522 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavage therapy alone
Number of subjects: 212
Study 3764522 — intervention group
Group type: COMPARATOR
Intervention: Mezlocillin (historical controls)
Number of subjects: 212
Study 31498169 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian residents
Number of subjects: 505
Study 31498169 — intervention group
Group type: COMPARATOR
Intervention: Non-Asian residents
Number of subjects: 505
Study 28494067 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary vitamin K1 intake (highest tertile)
Number of subjects: 5860
Study 28494067 — intervention group
Group type: COMPARATOR
Intervention: Lowest dietary vitamin K1 intake (lowest tertile)
Number of subjects: 5860
Study 25827255 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH 1-84
Number of subjects: 46
Study 25827255 — intervention group
Group type: COMPARATOR
Intervention: Calcium and colecalcipherol
Number of subjects: 46
Study 23307678 — intervention group
Group type: EXPERIMENTAL
Intervention: Total disc replacement (TDR)
Number of subjects: 173
Study 23307678 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary rehabilitation (MDR)
Number of subjects: 173
Study 21922974 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation of the frontal recess
Number of subjects: 40
Study 21922974 — intervention group
Group type: COMPARATOR
Intervention: Conventional functional endoscopic sinus surgery (Draf I procedure)
Number of subjects: 40
Study 18948425 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole (200 mg twice daily)
Number of subjects: 58
Study 18948425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 17094745 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard laparoscopic (SL)
Number of subjects: 40
Study 17094745 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand‐assisted laparoscopic (HAL)
Number of subjects: 40
Study 14988448 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy protein diet (DP, 2400 mg Ca/d)
Number of subjects: 50
Study 14988448 — intervention group
Group type: COMPARATOR
Intervention: Mixed protein sources diet (MP, 500 mg Ca/d)
Number of subjects: 50
Study 14988448 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets during energy restriction
Number of subjects: 50
Study 11412288 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP
Number of subjects: 40
Study 11412288 — intervention group
Group type: COMPARATOR
Intervention: ZEEP
Number of subjects: 40
Study 9669391 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐albumin colloid (AC)
Number of subjects: 51
Study 9669391 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐human serum albumin (HSA)
Number of subjects: 51
Study 9669391 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐sulfur colloid (SC)
Number of subjects: 51
Study 9669391 — intervention group
Group type: EXPERIMENTAL
Intervention: All agents
Number of subjects: 51
Study 9669391 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed imaging or localization alone
Number of subjects: 51
Study 8054835 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cooling of the contralateral hand in water at 16 degrees C for 2 min, repeated six times at randomized time intervals.
Number of subjects: 20
Study 3041558 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 152
Study 3041558 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 152
Study 1391671 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.125 mg
Number of subjects: 45
Study 1391671 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 45
Study 1391671 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 15 mg
Number of subjects: 45
Study 1391671 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg
Number of subjects: 45
Study 1391671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 332099 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 120
Study 332099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31492652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod 1.0 mg
Number of subjects: 1320
Study 31492652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod 0.5 mg
Number of subjects: 1320
Study 31492652 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1a
Number of subjects: 1320
Study 27418639 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) treatment
Number of subjects: 224
Study 27418639 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 224
Study 25552364 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF (dose-intense cyclophosphamide, epirubicin, and flurouracil)
Number of subjects: 2104
Study 25552364 — intervention group
Group type: EXPERIMENTAL
Intervention: EC/T (dose-dense, dose-intense epirubicin, cyclophosphamide, and paclitaxel)
Number of subjects: 2104
Study 25552364 — intervention group
Group type: COMPARATOR
Intervention: AC/T (doxorubicin, cyclophosphamide, and paclitaxel)
Number of subjects: 2104
Study 25552364 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher continuous ROR
Number of subjects: 2104
Study 25552364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic subtypes (compared with luminal A)
Number of subjects: 2104
Study 25552364 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-luminal tumors
Number of subjects: 2104
Study 23557429 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar I
Number of subjects: 51
Study 23557429 — intervention group
Group type: COMPARATOR
Intervention: Bipolar II
Number of subjects: 51
Study 23557429 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 21610239 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (60 mg/d for 14 days with a 5-day taper)
Number of subjects: 250
Study 21610239 — intervention group
Group type: COMPARATOR
Intervention: Intratympanic methylprednisolone (4 doses over 14 days of 40 mg/mL injected into the middle ear)
Number of subjects: 250
Study 19904567 — intervention group
Group type: EXPERIMENTAL
Intervention: PSE-enriched margarine (2.5 g/day of plant stanols)
Number of subjects: 28
Study 19904567 — intervention group
Group type: COMPARATOR
Intervention: Control margarine
Number of subjects: 28
Study 16739847 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-letting therapy combined with tapping Huatuo Jiaji (EX-B2) on the back by plum-blossom needle, once daily for 6 times (1 course)
Number of subjects: 95
Study 16739847 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture at points of the four limbs, once daily for 12 times (1 course)
Number of subjects: 95
Study 15534521 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive total knee replacement
Number of subjects: 40
Study 15534521 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard technique)
Number of subjects: 40
Study 15534521 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 11673746 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 12
Study 11673746 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study 9612237 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate (phi B) at a dose of 0.36 g.kg‐1.day‐1 for 24 hours
Number of subjects: 9
Study 7742261 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan
Number of subjects: 209
Study 7742261 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 209
Study 31192682 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA Ω‐3 (2.4 g/day; EPA 1.6 g and DHA 0.8 g)
Number of subjects: 53
Study 31192682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 28454533 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Treatment Orders (CTOs)
Number of subjects: 333
Study 28454533 — intervention group
Group type: EXPERIMENTAL
Intervention: Any exposure to CTO
Number of subjects: 333
Study 28454533 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO exposure
Number of subjects: 333
Study 28454533 — intervention group
Group type: COMPARATOR
Intervention: CTOs
Number of subjects: 333
Study 26304969 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month diabetes self-management education (DSME) program followed by 12 months of weekly group sessions and supplementary telephone support delivered by peer leaders
Number of subjects: 106
Study 26304969 — intervention group
Group type: COMPARATOR
Intervention: 3-month diabetes self-management education (DSME) program alone
Number of subjects: 106
Study 23100082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone treatment via major autohemotherapy (10 sessions)
Number of subjects: 68
Study 23100082 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine (48 mg/day for 3 months)
Number of subjects: 68
Study 23100082 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 68